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Abstract
Background: Cardiovascular disease (CVD) will remain the predominant cause of death and a major cause of
morbidity for the foreseeable future. Consequently, CVD prevention offers the greatest potential for the prevention
of premature mortality and the compression of morbidity.
Discussion: The 2013 guidelines of the American College of Cardiology and the American Heart Association
expand the eligibility for CVD preventive treatment based on the calculated 10-year CVD risk derived from the
pooled cohort equation to all persons who have a 10-year risk of CVD of ≥7.5% as estimated by the pooled cohort
equation. Previous analyses show that the use of a uniform 10-year risk threshold of 7.5% for all ages disadvantages
younger individuals for whom preventive therapy has most to offer. Here I show that reducing the threshold to 3%
in younger adults (women aged <66 years and men aged <56 years) will substantially increase the number of
cardiovascular events prevented at a similar number needed to treat to prevent one event. Importantly, this
increase in cardiovascular event prevention will occur in individuals with greater life expectancy.
Conclusion: Reducing the threshold 10-year risk of CVD derived from the pooled cohort equation for CVD
preventive treatment to 3% in younger adults (women aged <66 years and men aged <56 years) will more
effectively prevent premature mortality and compress morbidity to an older age.
Keywords: Prediction, Statins, Absolute risk
Background
Cardiovascular disease (CVD) will remain the predomin-
ant cause of death and a major cause of morbidity for
the foreseeable future [1–3]. Consequently, CVD pre-
vention offers the greatest potential for the prevention
of premature mortality and the compression of mor-
bidity [4]. Here, compression of morbidity refers to the
prevention or postponement of cardiovascular events to
a time closer to life expectancy, thereby restraining
growth in the health costs of the aging population [4].
The 2013 guidelines of the American College of Cardi-
ology and the American Heart Association (ACC-AHA)
expand the eligibility for CVD preventive treatment
based on the calculated 10-year CVD risk derived from
the pooled cohort equation to all persons who have a
10-year risk of CVD of ≥7.5% as estimated by the pooled
cohort equation [5, 6]. The pooled cohort equation cal-
culates an individual's 10-year risk of first hard athero-
sclerotic CVD event (defined as first occurrence of
nonfatal myocardial infarction, coronary heart disease
death, or fatal or nonfatal stroke) [6]. There is concern,
however, that a large proportion of younger adults
destined to experience a cardiovascular event have an
estimated 10-year risk that is below current thresholds
for lipid reduction therapy [7]. Commenting on the fail-
ure of current guidelines to recommend lipid-lowering
treatment for younger adults with low 10-year CVD risk
but high lifetime risk, Leening et al. recently argued for
a lifetime perspective in primary prevention of CVD
based on lifetime risk [8]. Here, I present a case for
lowering the 10-year risk threshold for preventive ther-
apy in younger adults to achieve greater compression of
morbidity with little additional cost per event prevented.
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Applying the pooled cohort equation to CVD prediction
The dominant predictor of any algorithm for CVD
prediction is age [9], with the risk increasing by more
than 2-fold for each additional decade from age 50 to
70 years in both women and men, even when all other
risk factors remain constant (Fig. 1). Thus, age alone will
cause an individual aged 50 with a 10-year risk of 3% to
have a 7.5% risk at age 60 and at least 15% risk at age
70. Age also predicts the number of additional years of
health that might be gained from CVD prevention, with
younger individuals expecting more additional years of
health from any CVD prevention strategy than older
individuals. There is debate about how effectively the
expanded indications for statin therapy for primary
prevention of CVD will prevent CVD. In their analysis
of the application of the ACC-AHA guidelines to the
National Health and Nutrition Examination Surveys of
2005–2010 Pencina found these guidelines mostly in-
creased statin eligibility for older adults who would not
have future cardiovascular events [10]. Moreover, Navar-
Boggan et al. describe how application of a 10-year fixed
risk threshold of 7.5% to the Framingham Offspring
cohort led to clinically significant variation in guideline
treatment performance across age- and sex-specific
groups, with decreased sensitivity for predicting future
CVD events in women and younger adults, indicative of
poor calibration of the prediction algorithm across the
spectrum of age in women and men [11]. Navar-Boggan
et al. concluded that cholesterol treatment recommenda-
tions could be improved by using age- and sex-specific
CVD risk thresholds [11].
Applying the pooled cohort equation to the Framingham
offspring cohort
Navar-Boggan et al. applied the pooled cohort equation
to the CVD event data from the Framingham Offspring
study, where the events were defined as a nonfatal
myocardial infarction, death from coronary heart dis-
ease, fatal or nonfatal stroke, peripheral arterial disease,
or heart failure [11]. They provide the percentage of
Framingham Offspring cohort participants meeting the
treatment threshold, and the sensitivity, specificity, posi-
tive predictive value and negative predictive value for
recommendation of therapy to men and women aged
40–55, 56–65 and 66–75 years who had events over the
subsequent 10 years, as determined from the pooled
cohort equation. These data provide the proportion of
each sex and age stratum that falls above the 10-year
risk threshold of 7.5% and the proportion of events that
occur in individuals above the threshold (Fig. 2). In
order to achieve optimal prevention of CVD, it is
necessary that the guidelines adequately capture individ-
uals destined to experience CVD who can be offered
preventive therapy. Figure 2 illustrates how a 10-year
risk threshold of 7.5% captured 95% of women and 96%
of men aged 66–75 years and 90% of men aged 56–65
years destined to have a cardiovascular event over the
next 10 years. However, this threshold of 7.5% captured
less than 50% of women and men aged 40–55 years and
women aged 56–65 years destined to have a cardiovas-
cular event.
The ACC-AHA guidelines recommend that lifetime
risk estimation be used as a communication strategy for
adults younger than 60 years who are free of atheroscler-
otic CVD and not candidates for lipid-lowering therapy,
and state that it is reasonable to offer treatment with a
moderate intensity statin to adults without CVD and
diabetes who have a 10-year CVD risk of 5–7.5% [5].
Navar-Boggan et al. discuss how reducing the threshold
risk from 7.5 to 5% improved sensitivity and specificity
for men and women aged less than 66 years [11], but a
threshold of 5% still failed to capture many women aged
56–66 years and women and men aged 40–55 years
destined to have a cardiovascular event (Fig. 2). By
contrast, a reduction in threshold to 3% resulted in a
greater proportion of younger adults above the 3%
threshold and at the same time enabled the capture of a
greater proportion of those destined to experience a
cardiovascular event. Reducing the threshold from 7.5 to
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Fig. 1 Impact of age on predicted 10-year risk of a cardiovascular
event. For a woman (solid columns) with total cholesterol 213 mg/
dl, HDL-C 50 mg/dl, untreated systolic BP 130 mmHg, nonsmoker,
with diabetes, her estimated 10-year risk of a cardiovascular event is
3%, 7.2%, and 18.7% at ages 50, 60, and 70. For a man (open
columns) with total cholesterol 213 mg/dl, HDL-C 50 mg/dl, untreated
systolic BP 115 mmHg, nonsmoker, without diabetes, his estimated
10-year risk of a cardiovascular event is 3%, 7.3%, and 15.1% at ages 50,
60, and 70. Predicted 10-year risk was calculated using the pooled
cohort equation [6]
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3% increased the proportion of women aged 40–55 years
above the threshold from 11 to 25% and increased the
proportion of events occurring in those above the
threshold from 36 to 61% (Fig. 2). Similarly, the propor-
tion of men aged 40–55 years above the threshold
increased from 32 to 73% and the proportion of events
occurring in those above the threshold increased from
48 to 90%. Moreover, the proportion of women aged
56–65 years above the threshold increased from 29 to
73% and the proportion of events occurring in those
above the threshold increased from 49 to 91%. Further-
more, reduction of the threshold from 7.5 to 3% reduced
the 10-year event rate in people below the threshold
from 5 to 4% for women aged 40–55 years, from 14 to
7% for men aged 40–55 years, and from 8 to 4% for
women aged 56–65 years. These event rates from the
Framingham Offspring cohort are higher than predicted
by the pooled cohort equation for a 3% CVD risk thresh-
old because the pooled cohort equation does not use
age- and sex-specific CVD risk thresholds [11].
Reducing the threshold risk for eligibility necessarily
increases the number of individuals who become eligible
for lipid-lowering therapy, with concern that treating
more people with statins for longer (because they are
younger) will increase the number who experience an
adverse event from therapy. However, the risk of adverse
events needs to be balanced against the potential bene-
fits of therapy. Pandya et al. showed that lowering the
10-year threshold from 7.5% to as low as 3% would avert
more atherosclerotic cardiovascular events cost
effectively, although they failed to take account of the
decreased sensitivity of the pooled cohort equation for
predicting future CVD events in women and younger
adults [12]. Limiting the lower threshold to women aged
<66 years and men aged <56 years is likely to be even
more cost effective because it would produce little
change in the proportion of individuals above the thresh-
old predicted to have a cardiovascular event, and thus
would have little effect on the cost per event prevented.
For a threshold of 7.5% in comparison with 3%, the
proportion of individuals above the threshold predicted to
have a cardiovascular event during the next 10 years was
23% and 18% for women aged 40–55 years, 28% and 23%
for men aged 40–55 years, and 19% and 14% for women
aged 56–65 years, respectively. The predicted number
needed to treat for 10 years to prevent one cardiovascular
event can be calculated from the proportion of individuals
predicted to have an event and the percentage reduction
in event rate from therapy. Assuming that lipid-lowering
therapy reduces the CVD event rate by 25% [13, 14], for a
threshold of 7.5% in comparison with 3%, the number
needed to treat is 17.4 and 22.2 for women aged 40–55
years, 14.3 and 17.4 for men aged 40–55 years, and 21.1
and 28.6 for women aged 56–65 years. Importantly, a
Fig. 2 Relationship between the percentage of individuals with
predicted 10-year risk≥ threshold and the percentage of cardiovascular
events occurring in these individuals, for different sex and age strata
and for thresholds of 7.5%, 5% and 3%. Data were derived from the
analysis of Navar-Boggan et al. [11]
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threshold of 3% would result in statin therapy being of-
fered to individuals who would otherwise experience an
event while waiting for their risk to reach the threshold of
7.5%. Thus, for 1000 women aged 40–55 years, an add-
itional 20 women destined to experience an event over the
next 10 years would be offered statin therapy, and for
1000 men aged 40–55 years, an additional 78 men des-
tined to experience an event over the next 10 years would
be offered statin therapy. Moreover, for 1000 women aged
56–65 years, an additional 47 women destined to experi-
ence an event over the next 10 years would be offered sta-
tin therapy.
If one assumes that lowering the threshold risk for eli-
gibility does not change the cost per individual treated,
then the similar numbers needed to treat for threshold
risks of 7.5% and 3% for women aged <66 years and
men aged < 56 years indicate similar cost effectiveness.
Importantly, the lower threshold risk threshold is likely
to be more cost effective because starting statin therapy
at a younger, rather than older, age is predicted to result
in more life years gained at lower cost per life year
gained [15]. Although adherence to prescribed therapy
for primary prevention is often poor and results in
reduced efficacy and increased costs of such approaches,
Helin-Salmivaara et al. reported that persons aged
45–74 years are more likely to continue statin use
than younger or older age groups [16].
Previous attempts to improve treatment decisions
based on 5- and 10-year risk have included the estima-
tion of 30-year and lifetime risk [1–3, 17], with the
intention to identify individuals of younger age with
higher 30-year or lifetime risk who might benefit from
preventive therapy. Such a strategy might lead to offer-
ing preventive therapy to a greater proportion of youn-
ger individuals destined to experience a cardiovascular
event within 10 years. However, it is not known what
30-year or lifetime risk threshold should guide decisions
or how effectively such a strategy would capture individuals
aged 40–55 years who are destined to have a cardiovascular
event well before their predicted life-expectancy. Import-
antly, treatment guidelines based on 30-year and lifetime
risk do not incorporate an adjustment for the greater
potential gain in years free of a cardiovascular event
for younger individuals offered CVD preventive therapy.
Compression of morbidity and reduction in health care
costs are best achieved by CVD prevention in younger in-
dividuals with greater potential years of life free of CVD,
not elderly individuals approaching the end of their life
who may have not only a high CVD risk but also a high
risk of death from non-cardiovascular causes. The present
proposal to use a 10-year predicted risk threshold of 3%
applies only to women and men aged 40–55 years and
women aged 56–65 years. The threshold of 7.5% is quite
satisfactory for women and men aged 66–75 years and
men aged 56–65 years (Fig. 2). The increased number of
younger adults offered CVD preventive therapy resulting
from a reduction in risk threshold to 3% might be
counter-balanced by the withdrawal of CVD preventive
therapy from individuals approaching the end of life, for
whom polypharmacy may produce more harm than good
[18], and for whom the potential for CVD preventive
therapy to extend life free of morbidity is small, such as
for nursing home residents [19]. In a pragmatic random-
ized clinical trial Kutner et al. recently reported that
withdrawal of statin therapy in adults with limited life
expectancy is safe and may be associated with benefits
including improved quality of life, use of fewer nonstatin
medications, and a corresponding reduction in medication
costs [20].
There are several arguments supporting a lower thresh-
old 10-year predicted risk for prescribing lipid-lowering
therapy in younger adults. Firstly, the high prevalence of
obesity is accompanied by an increased cardiovascular risk
in younger adults [21]. Secondly, younger adults are likely
to gain more years of health from prevention of cardiovas-
cular events than older adults, leading to the compression
of morbidity and reduced heath care costs. Thirdly, in
addition to lower mortality, morbidity and better quality of
life in older age, improved cardiovascular health in middle
age predicts reduced incidence of cancer, end-stage renal
disease and dementia, further contributing to compression
of morbidity [22–27]. Lastly, as discussed, lowering the
threshold for younger adults prevents many more cardio-
vascular events in younger adults at a similar cost per event
prevented as achieved by a threshold of 7.5%. Atheroscler-
otic disease develops over decades and these arguments for
a lower risk threshold for CVD preventive therapy in
younger adults are supported by evidence for the long-term
impact of risk factors such as blood pressure and choles-
terol levels on cardiovascular risk [8, 28, 29].
Limitations
This analysis has limitations. It is based on historical
data from the Framingham Offspring Study and may not
be representative of contemporary communities. More-
over, the event data from the Framingham Offspring
Study included peripheral arterial disease and heart
failure, which are not included in the pooled cohort
equation [6, 11]. However, the Framingham Offspring
Study contributed to the derivation cohort used for the
pooled cohort equation [6], and similar discrimination
by the ACC-AHA guidelines against younger individuals
at CVD risk was reported for the National Health and
Nutrition Examination Surveys [10]. Older age and male
sex are well-recognized risk factors for cardiovascular
events and the differences in performance of the pooled
cohort equation in women and men of different age
strata are likely to be reflected in other communities. It
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has been argued that the pooled cohort equation over-
estimates risk [30]. Nevertheless, despite possible inac-
curacies in the predicted risk, the events recorded from
the Framingham Offspring Study are real. It is, however,
acknowledged that any risk algorithm requires cali-
bration in the population to which it will be applied and,
as demonstrated by Navar-Boggan et al., treatment re-
commendations could be improved by using age- and
sex-specific CVD risk thresholds [11]. There is no such
thing as a perfect threshold, and there will always be a
trade-off between sensitivity for predicting events and
the number above the threshold for whom treatment is
recommended. It is necessary to balance the costs of
intervention and potential harm from the therapy against
the benefits of prevention and postponement of cardiovas-
cular events. Moreover, there is uncertainty about the
impact of any guidelines, and randomized trials may be
necessary to determine which of different guidelines has
maximum impact on CVD event rate and produces great-
est compression of morbidity [31].
Conclusions
The use of a uniform 10-year risk threshold of 7.5% for
all ages disadvantages younger individuals for whom
preventive therapy has most to offer [10, 11]. Reducing
the threshold to 3% in younger adults (women aged
<66 years and men aged <56 years) will substantially
increase the number of cardiovascular events prevented
at a similar cost per event prevented. Importantly, this
increase in cardiovascular event prevention will pre-
dominantly occur in younger individuals in whom the
prevention of events will compress morbidity to an older
age. Although this analysis is focused on the ACC-AHA
guidelines for lipid-lowering therapy, these arguments
apply equally to blood pressure-lowering and other CVD
preventive strategies.
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